• Facebook
  • Instagram

©2019 by Synchronicity Holistic. Proudly created with Wix.com


Synchronicity Holistic's Wellness Center is committed to bringing their patients relief. To learn more about how we can help suggest remedies for you, please visit us during store hours to receive a free consultation


While we cannot claim to "treat" our patients, we can offer relief .


An active compound in marijuana called tetrahydrocannabinol (THC) has been found to promote the removal of toxic clumps of amyloid beta protein in the brain, which are thought to kickstart the progression of Alzheimer's disease. The finding supports the results of previous studies that found evidence of the protective effects of cannabinoids, including THC, on patients with neurodegenerative disease.


The endocannabinoid system controls bronchospasm and airway dilation. Only very small doses of THC are required for the dilation of lung airways. In addition, CBD’s anti-inflammatory effects in asthma can also be helpful, which suggests using THC and CBD in combination. The terpene pinene, commonly found with THC, has bronchodilator activity as well. Vaping can be helpful for acute attacks but it must be used very carefully (medical supervision?), as individual sensitivity to smoke or vapor may cause unwanted bronchospasm. 


The very large number of cannabinoid receptors  (CB-1 and CB-2) throughout the gastrointestinal system serves as the basis for the effective treatment of many GI  disorders, including vomiting, diarrhea, inflammation and cramping found in Crohn’s Disease and Irritable Bowel Syndrome (IBS). 


Treating depression with cannabis currently lacks supporting data and is generally not recommended. However, carefully using CBD for the anxiety and THC for the insomnia and stress which frequently accompany depression can be very helpful. 


CBD can helpful for inflammation and THC for pain. (See arthritis) 


Historically cannabis has been used to treat the nausea and vomiting, neuropathy, pain, insomnia, and appetite suppression associated with HIV and its treatment.


Oral cannabis has been shown to be very effective treatment for insomnia and other sleep disorders. THC in a 5-7.5mg dose taken orally an hour before sleep is a common recommendation; however, dosage adjustments (e.g. down or up) may be required depending on individual uniqueness in sleep patterns or sensitivity to THC psychoactivity.


As the use of medical cannabis is embraced, there is an increase in its use for the treatment of the rheumatic diseases. Main benefits are it’s anti-inflammatory, pain relieving, and immunomodulatory properties. There are many conventional options to treat inflammation, including numerous biological medications, but this is not true for the treatment of chronic pain. A high CBD cannabis tincture can offer relief and can also be complemented with a topical preparation to treat a specific area.


Based on the large number of CB-1 receptors in the hippocampus, amygdala, and other brain structures the endocannabinoid system is thought to regulate anxiety. Using CBD can therefore be quite effective in treating anxiety, as can low doses of THC. Limonene and linalool, terpenes commonly found in cannabis, can add to the anti-anxiety effect. 


Observationally, small doses of THC under 2.5mg sublingually have been used to encourage hyperfocus in ADD patients. However, using cannabis to treat symptoms of ADD is extremely controversial because of the potential for THC to impair the neurological development of young brains. The hope is that research will lead to the development of optimal cannabis ADD regimens.


Since inflammation, pain, and neuropathy are major components of carpal tunnel syndrome, cannabis is a logical remedy.  


Skin inflammation can be reduced by topical application of CBD and THC, making cannabis useful in the treatment of dermatitis and other skin conditions. Since it is unclear whether CBD, THC or a combination of both are optimal, experimentation with different topical products may be necessary. 


A preliminary study in 2011 of cannabis use in fibromyalgia showed effectiveness in treating pain, stiffness, and insomnia. Low doses of THC have been successful along with CBD added to mitigate psychoactive THC side effects. 


Oral cannabis is commonly used to treat the nausea and vomiting associated with conventional hepatitis C drug therapy. 


This is your item description. Use this space to add a description of the services, products, team members or any other items you want to highlight on your site. Have a lot to say? Easily turn any item into a full page by clicking ‘Create a page from this item’ in the edit panel.


With the current opioid crisis many individuals are seeking alternatives to treat both acute and chronic pain. The pain relieving and anti-inflammatory properties of cannabis can be used as an adjunct to current therapies to enhance their effectiveness or as a single agent. In addition to THC/CBD combinations the raw form of THC, known as THCa, offers pain relief without being psychoactive.


Despite the lack of clinical studies there is substantial anecdotal evidence supporting the use of CBD-rich cannabis oil in the treatment of Asperger’s syndrome and other types of autism. More studies are obviously needed to confirm these findings. 


While there is lots of data supporting the use of cannabis for anorexia in cancer or HIV/AIDS, little research has been done on the effectiveness of cannabis in treating anorexia nervosa. While it theoretically makes sense, anorexia nervosa is so complex that cannabis is not usually recommended at the present time. 


Historically cannabis has been used to treat side effects of chemotherapy (e.g. nausea, vomiting, neuropathy), as well as pain, insomnia, stress, and appetite suppression. Only anecdotal evidence currently exists for direct cancer activity (no studies as yet) but data is accumulating. 


Recent preliminary evidence shows that oral cannabis may offer neuroprotective and anti-inflammatory effects to mildly sedate patients with dementia. Multiple daily doses of small amounts of THC have been recommended. 


CBD and THC are neuroprotective for the optic nerve and THC also lowers intraocular pressure. Both are recommended orally as adjuncts to conventional glaucoma treatment but not alone, as THC has been found to not lower intraocular pressure consistently. 


Many individuals have experienced comfort and relief using cannabis as part of their MS regimen. Pain relief is obtained from THC or its non-psychoactive form THCa. Muscle relaxation, spasticity, and tone are improved with CBD. Various delivery methods of vaping, tinctures, and edibles are available to help determine one’s optimum level of comfort. Tinctures offer the advantage of being able to easily titrate doses when starting cannabis.


Cannabis has been found to be effective as prophylaxis for migraine headaches, using small doses of THC to reduce headache frequency and intensity. It also can treat pain and nausea after headache onset using larger THC doses, with buffer doses of CBD to mitigate against increased THC psychoactivity.


Seizure  disorders are primarily treated with anti-epilepsy drugs. It is thought that 30% of these disorders do not respond to these medications. Individuals that find themselves in this situation search for options and much attention has been given to the cannabinoids, specifically CBD. Early studies have shown that CBD reliably delivers a range of anticonvulsant effects without intoxication. A severe form of epilepsy, Dravet syndrome, strikes very young children and can be catastrophic. The parents of a young girl, Charlotte Figi, found that CBD oil, unlike traditional therapies, halted her seizures.  Popular CBD-rich varieties include ACDC, Harlequin and Ringo’s Gift. CBD-rich tinctures are recommended in a 20:1 ratio or higher. Two other cannabinoids, THCA and CBDA, are being explored as well. Like CBD they both are non-psychoactive.

GW Pharmaceuticals developed Epidiolex, which contains CBD dissolved in sesame oil. Epidiolex was the first prescription pharmaceutical of CBD approved by the FDA on June 25, 2018.